2026-19231RuleWallet

Diphenidine Banned: Obscure Drug Joins Schedule I No-Medical-Use Club

Published Date: 9/21/2026

Rule

Summary

Starting October 21, 2026, diphenidine and its related forms will be officially listed as Schedule I drugs, meaning they’re considered highly controlled with no accepted medical use. This change affects anyone who makes, sells, studies, or even possesses diphenidine, bringing strict rules and serious penalties. The move helps the U.S. follow international drug laws and keep communities safer.

Analyzed Economic Effects

4 provisions identified: 1 benefits, 3 costs, 0 mixed.

Diphenidine placed in Schedule I

On October 21, 2026, diphenidine (including its salts, isomers, and related forms) is officially listed in Schedule I. This means possession, manufacture, sale, import, export, or other handling of diphenidine is unlawful unless you are authorized, and unauthorized activity may lead to administrative, civil, or criminal sanctions.

You must register to handle diphenidine

Any person who wants to handle diphenidine (manufacture, distribute, import, export, research, or possess) must register with the DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. If you currently handle diphenidine and are not registered, you must apply for registration and may not continue handling diphenidine unless DEA approves your application.

Research continuation window and expedited hearings

If, on October 21, 2026, you are conducting research on diphenidine and are already registered to research another Schedule I substance, you may continue that diphenidine research if you submit a completed registration or modification application within 90 calendar days after the rule takes effect. If DEA serves an order to show cause proposing denial, you may not continue research; if you request a hearing it will be held on an expedited basis not later than 45 calendar days after the request, unless you ask for a later date.

Schedule I compliance duties for registrants

Registered handlers of diphenidine must meet Schedule I controls: security and employee screening, labeling and packaging rules, manufacturing quotas, inventory (initial inventory on first handling and then every two years), records and reporting (including reports to Automation of Reports and Consolidated Orders System), order form use, and lawful import/export. Any handling not authorized under the Controlled Substances Act may result in administrative, civil, or criminal sanctions.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
9/21/2026
10/21/2026

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register